× Digital News Videos Health & Science Lifestyle Opinion Education Columnists Moi Cabinets Arts & Culture Fact Check Podcasts E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Health Magazine TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise VAS E-Learning Digger Classified Jobs Games Crosswords Sudoku The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS
×
Men
menu search
Standard Logo
Home / Health & Science

Covid-19 vaccine jitters over second dose delay

HEALTH & SCIENCEBy GRAHAM KAJILWA | Mon,Apr 26 2021 14:20:00 EAT
By GRAHAM KAJILWA | Mon,Apr 26 2021 14:20:00 EAT

 A medical worker prepares a dose of Oxford/AstraZeneca's COVID-19 vaccine at a vaccination centre in Antwerp, Belgium March 18, 2021. [REUTERS/Yves Herman]

Kenyans will wait a little bit longer than the eight-week period to get their second dose of the Oxford/AstraZeneca vaccine after a global shortage occasioned by a surge in Covid-19 cases in India, the main manufacturer of the jab.

Speaking at a media briefing, Health Cabinet Secretary Mutahi Kagwe revealed that the delivery date for the next consignment of the vaccine may go beyond May, but experts hope that the second dose will be in on time before the 12-week maximum period between the first and second dose.

The CS says that the government plans to acquire two million doses of Pfizer-BioNTech and Johnson & Johnson vaccines.

Johnson & Johnson vaccine is a one-dose prescription while Pfizer-BioNTech is in two doses, just like Oxford/AstraZeneca.

Covid 19 Time Series

 

Kagwe said Pfizer-BioNTech and Johnson & Johnson will be acquired through the African Union (AU) and once the negotiations are done, they will be delivered.

Timelines for their delivery were, however, not given.

“Once we have concluded our deal, we expect one million doses for Pfizer-BioNTech and maybe another one million for Johnson & Johnson once production is ramped up,” said Kagwe. “That combined with what we can get from Covax facility (in this case AstraZeneca) should be able to allow us to continue with the vaccination process.”

He said these doses are essential to back up and support what the country will be expecting from Covax.

It was expected by now that Kenya should have in the stores 2.5 million doses of the second batch of the AstraZeneca vaccine for the second phase of vaccination.

However, a new wave of the disease in India, where the vaccine is manufactured, is the reason behind the delay of the jab.

 

Related Topics

Share this story
.
RECOMMENDED
.
LATEST JOB OPPORTUNITIES ON STANDARDJOBS